The data in Figure 7D indicate that MSC and SLM similarly potentiate the antitumor activity of axitinib, a Food and Drug Administration (FDA)-approved VEGFR-targeting agent for the treatment of relapsed ccRCC patients. This evidence concerns the gene KDR and nonpapillary renal cell carcinoma.